Bristol-Myers Squibb Co vs T Rowe Price Group Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while T Rowe Price Group Inc trades at $116.99 (market cap $24.26B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.4× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| BMY | TROW | |
|---|---|---|
Market Cap | $129.94B | $24.26B |
Sector | Health | Financials |
52-Week High | $65.89 | $121.68 |
52-Week Low | $42.60 | $86.19 |
Enterprise Value | $163.92B | $21.46B |
Dividend Yield | 3.96% | 4.57% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →